

an informed treatment choice

Scroll for more >

Jamie-Lynn S. has taken KESIMPTA® and has been compensated for her time.

Important Safety Information Who should not take KESIMPTA?

Do NOT take KESIMPTA if you've had a lifethreatening injection-related reaction to it, an allergic reaction to ofatumumab, or have active hepatitis B virus (HBV) infection.

You're on Your Way



What's most important to you in a treatment?

No one knows better than you.



Finding the right treatment for you may feel overwhelming, but it is possible. With this guide and expert advice from your doctor, you're on your way to a decision you can feel good about.

Ready to begin? You've got this! ~

Important Safety Information (cont)

What is the most important information I should know about KESIMPTA?

KESIMPTA can cause serious side effects such as:

Infections. Serious infections, which can be



Where to Start?

Making an informed decision starts with asking informed questions.

Tap icons or scroll to learn more ~















Important Safety Information (cont)

life-threatening or cause death, can happen during treatment with KESIMPTA. If you have an active infection, your health care provider (HCP) should delay your treatment with





Powerful Results*



KESIMPTA® is a B-cell treatment proven* to:

Reduce Relapses

Reduce Active Lesions

Slow Disability Progression

*In 2 studies vs teriflunomide.

Dive deeper into the study results

Important Safety Information (cont)

KESIMPTA until your infection is gone. KESIMPTA taken before or after other medicines that weaken the immune system may increase your risk of getting infections.





Wondering about treatment results?

Ask your doctor:

- What is a B-cell treatment? How does KESIMPTA® work?
- Are there reasons to start treating right away?
- What kind of results should I be looking for?
- Are there any concerns between doses I should be aware of?

Are there any reasons to start with a B-cell

therapy?

Full checklist of questions





Take a screenshot to use during your next doctor's visit.





What People Are Saying



In a real-world survey,* people taking KESIMPTA®:

- found the auto-injector pen **EASY TO USE**
- said monthly dosing was CONVENIENT



RMS, relapsing multiple sclerosis.

*Real-world 30-question survey of 105 US patients (aged ≥18) diagnosed with RMS for 1+ years, who took KESIMPTA with the auto-injector pen within previous 12 months. On a scale of 1-5, 89.5% of patients rated it a 4 or 5 (5 being most positive) on overall ease of use and ease of monthly dosing schedule. Questionnaire not validated.

Hear from others taking KESIMPTA (>)



Important Safety Information (cont)

Tell your HCP right away if you have any infections or get any symptoms including painful and frequent urination, nasal congestion, runny nose, sore throat, fever, chills,



Not the Injection You'd Expect



The pen features help you get comfortable taking KESIMPTA® yourself.

— No visible needle

Thinner than a pediatric needle*

Built-in guides

- Audible and visual progress indicators
- 2 clicks tell you it's almost done

*KESIMPTA pens come with a staked needle of 29-gauge. Pediatric needles average between 23-gauge and 25-gauge.

See 3 reasons to consider the pen

Important Safety Information (cont)

cough, or body aches.

HBV reactivation. If you have ever had HBV infection, it may become active again during or after treatment with KESIMPTA (reactivation).



Treatment Time



The KESIMPTA® auto-injector pen comes prefilled and ready to go when you are*—

TAKE IT JUST ONCE A MONTH.

ZENOVIA W.

Entrepreneur, Wellness Coach Switched to KESIMPTA in 2022



- *Take the KESIMPTA pen out of the refrigerator 15 to 30 minutes before injecting to allow it to reach room temperature.
- [†]Once monthly after 3 weekly starter doses.

Follow along as a real person takes KESIMPTA:

Watch Zenovia use the pen step by step (>)



Important Safety Information (cont)

If this happens, it may cause serious liver problems including liver failure or death. Before starting KESIMPTA, your HCP will do a blood test to check for HBV. They will also continue



Taking KESIMPTA®



There are plenty of training resources available, but someone from your health care team will show you how to use it first so you'll be ready on treatment day.

Here are the steps for injecting KESIMPTA*:

- ✓ Remove from fridge 15-30 mins to get to room temp
- ✓ Visually inspect for expiration date and liquid clarity
- Choose and clean the injection site
- √ Twist off cap only when ready to use. Discard cap, use within 5 mins
- ✓ Press firmly against skin at 90°. After the second click, the green indicator will stop moving. Remove pen
- ✓ Dispose in an FDA-cleared sharps container

Important Safety Information (cont)

to monitor you during and after treatment with KESIMPTA for HBV. Tell your HCP right away if you get worsening tiredness or yellowing of your skin or the white part of your eyes.



^{*}These are not the full instructions for use (IFU). Please see IFU for more information.



Wondering about taking treatment?

Ask your doctor:

- What are the options for taking treatments? How is KESIMPTA® taken?
- Do your patients find an auto-injector pen easy to use? Do they say if it hurts?
- Do you have a KESIMPTA auto-injector pen I could see or practice with?
- Of your treatment recos, what can I expect from my first dose? Will I need premedications?

Full checklist of questions



Take a screenshot to use during your next doctor's visit.





Convenient* Dosing





Take KESIMPTA® from THE COMFORT OF HOME,

ONCE A MONTH

—no premedications required.[‡]

Important Safety Information (cont)

 Progressive Multifocal Leukoencephalopathy (PML). PML may happen with KESIMPTA. PML is a rare, serious brain infection caused by a virus that may get worse over days or weeks.



^{*}In a real-world survey, 89.5% of people found the dosing schedule of the KESIMPTA auto-injector pen convenient. See full details on page 8.

[†]Once monthly after 3 weekly starter doses.

[‡]Only limited benefit of premedication was observed in relapsing MS clinical studies.

Take It With You





The KESIMPTA® Pen is

TRAVEL FRIENDLY*

and can be kept at room temperature for up to 7 days.

*KESIMPTA® pens must be refrigerated at 2 °C to 8 °C (36 °F to 46°F). Keep product in the original carton to protect from light until the time of use. Do not freeze. To avoid foaming, do not shake. If necessary, KESIMPTA may be stored at room temperature below 30 °C (86 °F) for up to 7 days and returned to the refrigerator, to be used within the next 7 days. If not used within those 7 days, discard the medicine.

Important Safety Information (cont)

PML can result in death or severe disability. Tell your HCP right away if you have any new or worsening neurologic signs or symptoms. These may include weakness on one side of your body,



Taking B-cell Treatments



There are factors to consider when it comes to treatment day.

KESIMPTA®	Other B-cell treatments*
Take it yourself	Administered by a health care provider
Take it at home or bring with you	Taken mainly in a medical facility, travel required
No premeds required [†]	Premeds recommended
No post-dose observation	Post-dose observation

^{*}B-cell treatments for RMS include: KESIMPTA, Ocrevus® (ocrelizumab),
Ocrevus® Zunovo™ (ocrelizumab and hyaluronidase-ocsq), and Briumvi® (ublituximab-xiiy). This is not a complete list of all the available treatments for RMS. The comparison pertains only to differences in administration and should not be considered a comparison of efficacy or safety. Please see each product's respective prescribing information for additional information, including indication, dosing, administration, and safety. Trademarks are the property of their respective owners.

Important Safety Information (cont)

loss of coordination in arms and legs, vision problems, changes in thinking and memory, which may lead to confusion and personality changes.



[†]Only limited benefit of premedication with corticosteroids, antihistamines, or acetaminophen was seen in RMS clinical studies.

B-cell Treatment Timing



Along with how treatments are taken, consider how long administration can take.

Administered yourself:

KESIMPTA®

<3-4 secs avg* auto-injection

1x monthly*

See full steps for injecting KESIMPTA here.

Administered by a health care provider:

Ocrevus® (ocrelizumab)

2-4 hrs infusion

2x yearly

Ocrevus® Zunovo™ (ocrelizumab and hyaluronidase-ocsa)

10 mins injection

2x yearly

Briumvi® (ublituximab-xiiy)

1-4 hrs[†] infusion

2x yearly

This is not a complete list of all the available treatments for RMS.[‡]

Important Safety Information (cont)

 Weakened immune system. KESIMPTA taken before or after other medicines that weaken the immune system could increase your risk of getting infections.



^{*}Typical administration time when ready to inject. Once monthly after 3 weekly starter doses.

⁺The 1st infusion of Briumvi takes 4 hrs. Subsequent infusions take 1 hr.

[‡]The comparison pertains only to differences in dosing and administration and should not be considered a comparison of efficacy or safety. Please see each product's respective prescribing information for additional information, including indication, dosing, administration, and safety. Trademarks are the property of their respective owners.



Wondering how treatments can fit into your life?

Ask your doctor:

- What are the different treatment schedules for different therapies?
- What steps are involved on a typical treatment day for those therapies?
- Will I need to take time off work or other downtime for treatment?
- Could I travel with KESIMPTA®?
 Are there storage requirements?

Full checklist of questions



For adults only.



Take a screenshot to use during your next doctor's visit.





Proven Safety Profile



Because it's so important, the safety of KESIMPTA® continues to be studied:



Check out the safety details

*KESIMPTA continues to be studied in an ongoing, open-label extension study. An open-label study is a type of study where participants are aware of the type of treatment they're being given. Interpreting results from open-label studies can be uncertain. They are not considered representative results, since participants chose whether to stay in the trial. After the original KESIMPTA studies, over 1700 people continued to participate for further evaluation, where they all took KESIMPTA. The goal of this extended study was to learn about the safety and tolerability of KESIMPTA in the long term, with a focus on injection-related reactions, malignancies, and serious infections for up to 7 years. No conclusions of clinical outcomes can be drawn. (September 25, 2024 data cut-off date.)

Important Safety Information (cont)

Before you take KESIMPTA, tell your HCP about all your medical conditions, including if you:

 Have or think you have an infection including HBV or PML.





Wondering about treatment safety?

Ask your doctor:

- When choosing a treatment, what are the safety considerations or side effects I should know about?
- Has the safety profile of KESIMPTA® been studied long term?
- What do your other patients experience on KESIMPTA? How long have they been on it?

Full checklist of questions





Take a screenshot to use during your next doctor's visit.






One-on-One Help



Novartis Patient Support[™] pairs you with a real person as your Coordinator.



You're not alone. Don't hesitate to ask for help.

Once enrolled, you can reach us at:

1-855-537-4678

8:30am-8:00рм ET, Mon-Fri

- Press Option 2 for insurance and financial support
- Press Option 3 for ongoing support



See What's Offered



Through Novartis Patient Support™, your Coordinator can connect you with help to:

- get started as soon as possible
- secure insurance coverage
- answer your questions
- access other support resources
- get KESIMPTA® delivered right to your door



Explore support details



Need Co-pay Help?





When using the KESIMPTA® Access Card, 97% of all claims cost



You can get started for free while we work with your health care provider to secure coverage.

*Limitations apply. Offer not valid under Medicare, Medicaid, or any other federal or state health insurance program. Patients with commercial insurance who are initially denied coverage may receive free KESIMPTA for up to 12 months while seeking coverage. Patients with commercial insurance who have coverage for KESIMPTA may receive up to \$18,000 in annual co-pay benefits. Novartis reserves the right to rescind, revoke, or amend this program without notice. Additional limitations may apply. Learn more about how to enroll and see complete Terms & Conditions at start.kesimpta.com.



Meet the KESIMPTA Crew



We share our treatment journeys to help you navigate yours...

Hear from Crew Members like:

ANDY M.

Dad, Account Executive, Chose KESIMPTA® as 1st treatment: 2022





ZENOVIA W.

Entrepreneur, Wellness Coach, Switched to KESIMPTA in 2022

We all have a story, it's time to take charge of yours. We got you!

THE KESIMPTA CREW

Unless otherwise indicated, all people in this guide live with relapsing MS, have taken KESIMPTA, and been compensated for their time.

Watch KESIMPTA Crew Stories (*)



Important Safety Information (cont)

Have ever taken, currently take, or plan to take medicines that affect your immune system. These medicines could increase your risk of getting an infection.





Wanting support for your treatment journey?

Ask your doctor:

- How quickly can I get started on KESIMPTA®?
- ☐ How much will it cost?
- Will my insurance cover it?
- Is there a KESIMPTA support program if I need help along the way?

Full checklist of questions



Take a screenshot to use during your next doctor's visit.





Quesiontime

With these Q's for your doctor, speak up to reach a decision together.



About Results

KESIMPTA® work? Are there reasons to start treating

What is a B-cell treatment? How does

- right away? What kind of results should I be
- looking for? Are there any concerns between doses I should be aware of?
- Are there any reasons to start with a B-cell therapy?



Scroll for more >

Return to Results Section >



Administration What are the options for taking

About Treatment

Do your patients find an auto-injector pen easy to use? Do they say if it hurts?


treatments? How is KESIMPTA taken?

I could see or practice with? Of your treatment recos, what can I expect from my first dose? Will I

Do you have a KESIMPTA auto-injector pen

need premedications? **Return to Administration Section**





What are the different treatment


treatment day for those therapies? Will I need to take time off work or

other downtime for treatment?

What steps are involved on a typical

Could I travel with KESIMPTA? Are there storage requirements?

For adults only



safety considerations or side effects I

long have they been on it?

Has the safety profile of KESIMPTA

About Available Support How quickly can I get started on KESIMPTA?

Return to Safety Section >

program if I need help along

the way?

How much will it cost?

Will my insurance cover it?

Is there a KESIMPTA support


should know about?

been studied long term?

What do your other patients

experience on KESIMPTA? How

Return to Support Section >



Have had a recent vaccination or are


- Have a history of liver problems.
- scheduled to receive any vaccinations. You should receive any required 'live' or

Important Safety Information (cont)

Click here for full Prescribing Information including Medication Guide.

Kesimpta® (ofatumumab) 20 mg injection





'live-attenuated' vaccines at least 4 weeks before you start treatment with KESIMPTA. You should not receive 'live' or 'live-attenuated' vaccines while you are being treated with KESIMPTA and until your HCP tells you that your immune system is no longer weakened.



What is KESIMPTA® (ofatumumab) injection?

Indication

KESIMPTA is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis

(MS) including clinically isolated syndrome (CIS), relapsing-remitting disease, and active secondary progressive disease. It is not known if KESIMPTA is safe or effective in children.

Important Safety Information Who should not take KESIMPTA?

Do NOT take KESIMPTA if you:

Have an active hepatitis B virus (HBV) infection. Have had an allergic reaction to ofatumumab

know about KESIMPTA?

or life-threatening injection-related reaction to

- KESIMPTA. What is the most important information I should
- KESIMPTA can cause serious side effects such as: • Infections. Serious infections, which can be lifethreatening or cause death, can happen during

treatment with KESIMPTA. If you have an active infection, your health care provider (HCP) should delay your treatment with KESIMPTA until your

infection is gone. KESIMPTA taken before or after

other medicines that weaken the immune system

may increase your risk of getting infections. Tell

your HCP right away if you have any infections or get any symptoms including painful and frequent urination, nasal congestion, runny nose, sore throat, fever, chills, cough, or body aches. • HBV reactivation. If you have ever had HBV infection, it may become active again during or after treatment with KESIMPTA (reactivation). If this happens, it may cause serious liver problems including liver failure or death. Before starting KESIMPTA, your HCP will do a blood test to check for HBV. They will also continue to monitor you during and after treatment with KESIMPTA

for HBV. Tell your HCP right away if you get

the white part of your eyes.

getting infections.

HBV or PML.

infection.

worsening tiredness or yellowing of your skin or

 Progressive Multifocal Leukoencephalopathy (PML). PML may happen with KESIMPTA. PML is a rare, serious brain infection caused by a virus that may get worse over days or weeks. PML can result in death or severe disability. Tell your HCP right away if you have any new or worsening neurologic signs or symptoms. These may include weakness on one side of your body, loss of coordination in arms and legs, vision problems, changes in thinking and memory, which may lead to confusion and personality changes.

• Weakened immune system. KESIMPTA taken

before or after other medicines that weaken

the immune system could increase your risk of

Before you take KESIMPTA, tell your HCP about

all your medical conditions, including if you:

Have or think you have an infection including

Have ever taken, currently take, or plan to take

medicines that affect your immune system. These

medicines could increase your risk of getting an

 Have a history of liver problems. Have had a recent vaccination or are scheduled to receive any vaccinations. You should receive any required 'live' or 'liveattenuated' vaccines at least 4 weeks before you start treatment with KESIMPTA. You should

not receive 'live' or 'live-attenuated' vaccines

while you are being treated with KESIMPTA

Whenever possible, you should receive any

system is no longer weakened.

and until your HCP tells you that your immune

'non-live' vaccines at least 2 weeks before you

start treatment with KESIMPTA. Talk to your HCP about vaccinations for your baby if you used KESIMPTA during your pregnancy. Are pregnant, think that you might be pregnant,

or plan to become pregnant. It is not known if

who can become pregnant should use birth

KESIMPTA and for 6 months after your last

control (contraception) during treatment with

treatment. Talk with your HCP about what birth

KESIMPTA will harm your unborn baby. Females

control method is right for you during this time. Are breastfeeding or plan to breastfeed. It is not known if KESIMPTA passes into your breast milk. Talk to your HCP about the best way to feed your baby if you take KESIMPTA. Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. How should I use KESIMPTA? See the detailed Instructions for Use that

comes with KESIMPTA for information about

and how to properly throw away (dispose of)

syringes.

use it.

for the first time.

and symptoms.

used KESIMPTA Sensoready® pens or prefilled

Use KESIMPTA exactly as your HCP tells you to

Your HCP will show you how to prepare and

inject KESIMPTA the right way before you use it

• Do not inject into areas where the skin is tender,

how to prepare and inject a dose of KESIMPTA

bruised, red, scaly or hard. Avoid areas with moles, scars, or stretch marks. **KESIMPTA** may cause serious side effects including: Injection-related reactions. Injection-related reactions are a common side effect of KESIMPTA. Injecting KESIMPTA can cause injection-related reactions that can happen within 24 hours (1 day) following the first injections and with later

injections. There are two kinds of reactions:

• At or near the injection site: redness of

the skin, swelling, itching, and pain. Talk to

That may happen when certain substances

are released in your body: fever, headache,

hives, trouble breathing, swelling of the face,

feeling faint, or chest tightness. Contact your

these signs and symptoms, especially if they

become worse or you have new severe signs

of reactions after subsequent injections. It

eyelids, lips, mouth, tongue and throat, and

pain in the muscles, chills, tiredness, rash,

HCP right away if you experience any of

your HCP if you have any of these signs

could be a sign of an allergic reaction, which can be serious. · Low immunoglobulins. KESIMPTA may cause a decrease in some types of antibodies. Your HCP will do blood tests to check your blood

• Liver damage. KESIMPTA may cause liver

damage. Your HCP will do blood tests to check

your liver before you start KESIMPTA and while

you take KESIMPTA if needed. Tell your HCP right

away if you have any symptoms of liver damage

immunoglobulin levels.

such as:

headache.

o nausea vomiting unusual darkening of the urine feeling tired or weak The most common side effects of KESIMPTA include:

Upper respiratory tract infection, with symptoms

www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full <u>Prescribing Information</u> including

- yellowing of the skin and eyes (jaundice)
 - · Headache. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit

such as sore throat and runny nose, and

9/25



Medication Guide.

Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936-1080

Return to previously viewed page >

© 2025 Novartis

FA-11492702